InflaRx N.V.
IFRX
NASDAQ·Healthcare·Biotechnology·Mkt cap $328.5M
$2.13
▼ -4.48%
P/E
-3.04
Mkt Cap
$328.5M
52-Wk Range
$0.80–$2.95
52-Week Range
$0.80 - $2.95
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 27.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- First-in-class C5a inhibitor technology with novel mechanism of action
- Phase III clinical data demonstrating efficacy in rare debilitating diseases
- Strategic partnerships with global pharma leaders (Merck & Co.)
- Focused pipeline targeting high-value, underserved rare disease markets
Bear Case
1 risk
- High volatility (beta 2.5). Larger-than-normal price swings expected.
Growth
Revenue decline expected
Vilobelimab regulatory approval and commercialization potential
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Weak
-7.1% over 3m
Quality
Solid
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying IFRX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 6, 2026
Reported EPS of -$0.11 vs -$0.07 consensus (-65.1% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-65.1%
Revenue trend · last 8Q
—
—
—
-100%
+520%
-81%
—
—
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$7.5K
$145.2K
-$496
$0
$46.2K
$27.9K
-$41.1K
$0
Margins · last 8Q
Gross
—
Profit
—
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Raymond James · $9.00 · May 13, 2026
vs Industry
How IFRX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related